Clinical & Translational Oncology

, Volume 8, Issue 4, pp 225–227 | Cite as

Bad patients meet good drugs



Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Manning G, Whyte DB, Martínez R, Hunter T, Sudarsanam S. The protein kinase complement of the human genome. Science. 2002;298(5600):1912–34.PubMedCrossRefGoogle Scholar
  2. 2.
    Blume-Jensen P, Hunter T. Oncogenic kinase signalling. Nature. 2001;411(6835): 355–65.PubMedCrossRefGoogle Scholar
  3. 3.
    Ciardiello F, De Vita F. Epidermal growth factor receptor (EGFR) inhibitors in cancer therapy. Prog Drug Res. 2005;63:93–114.PubMedCrossRefGoogle Scholar
  4. 4.
    Twombly R. Failing survival advantage in crucial trial, future of Iressa is in jeopardy. J Natl Cancer Inst. 2005;97(4):249–50.PubMedCrossRefGoogle Scholar
  5. 5.
    Shepherd FA, Rodrigues PJ, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005;353(2):123–32.PubMedCrossRefGoogle Scholar
  6. 6.
    Radich JP. Philadelphia chromosome-positive acute lymphocytic leukemia. Hematol Oncol Clin North Am. 2001;15(1): 21–56.PubMedCrossRefGoogle Scholar
  7. 7.
    Druker BJ. Imatinib as a paradigm of targeted therapies. Adv Cancer Res. 2004;91: 1–30.PubMedGoogle Scholar
  8. 8.
    Laurent E, Talpaz M, Kantarjian H, Kurzrock R. The BCR gene and philadelphia chromosome-positive leukemogenesis. Cancer Res. 2001;61(6):2343–55.PubMedGoogle Scholar
  9. 9.
    Lugo TG, Pendergast AM, Muller AJ, Witte ON. Tyrosine kinase activity and transformation potency of ber-abl oncogene products. Science. 1990;247(4946):1079–82.PubMedCrossRefGoogle Scholar
  10. 10.
    O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348(11):994–1004.PubMedCrossRefGoogle Scholar
  11. 11.
    van der Zwan SM, DeMatteo RP. Gastrointestinal stromal tumor: 5 years later. Cancer. 2005;104(9):1781–8.PubMedCrossRefGoogle Scholar
  12. 12.
    Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science. 2001;293 (5531):876–80.PubMedCrossRefGoogle Scholar
  13. 13.
    Shah NP, Tran C, Lee FY, et al. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science. 2004;305(5682): 399–401.PubMedCrossRefGoogle Scholar

Copyright information

© FESEO 2006

Personalised recommendations